(Fiztasovimab)Biosimilar Reference Antibody-GS40271

货号：GS40271

Fiztasovimab is an investigational human monoclonal antibody being developed for the prevention and treatment of human cytomegalovirus (hCMV) infections. It functions as a neutralizing antibody with a distinct mechanism of action. Fiztasovimab specifically binds to the glycoprotein B (gB) of hCMV, a critical viral envelope protein. By binding to gB, it inhibits a key step in the viral life cycle—cell-to-cell spread—where the virus propagates directly from an infected cell to adjacent uninfected cells without being released into the extracellular fluid. This inhibition blocks the expansion of infection within tissues, offering a potential therapeutic strategy to control hCMV replication, particularly in immunocompromised patients (e.g., transplant recipients) and congenitally infected infants.